To Market, To Market—2003
作者： Shridhar Hegde , Jeffery Carter
DOI: 10.1016/S0065-7743(04)39025-1
关键词:
摘要: Publisher Summary This chapter discusses 27 drugs which were manufactured in the year 2003 related to cardiovascular, anticancer, allergic and respiratory diseases, male erectile dysfunction, attention deficit/hyperactivity disorder. The cardiovascular sector had four new entering market 2003: Crestor™ (rosuvastatin), Livalo ® (pitavastatin), Calblock (azelnidipine), a gradual-onset, long-acting calcium antagonist, Inspra™(eplerenone). anticancer field saw introduction of three drugs: Velcade (bortezomib), Erbitux (cetuximab), Bexxar (tositumomab). In two entities reached market: Rupafin (rupatidine fumarate) Xolair (omalizumab). area endocrine metabolic appeared on Somavert (pegvisomant) Aldurazyme (laronidase). Zavesca™ (miglustat), glucosylceramide synthase inhibitor, was introduced as first orally active treatment for type 1 Gaucher's disease. Following success Viagra (sildenafil) dysfunction (ED), phosphodiesterase 5 (PDE5) inhibitors launched: Cialis™ (tadalafil) Levitra™ (vardenafil). CNS represented by launch Strattera™ (atomoxetine). Two biologic immunosuppressive agents also Amevive (alefacept) Raptiva™ (efalizumab). A significant NBE last Humira™ (adalimumab). other notable launched FluMist™ (influenza virus live).
sci-hub.se 参考文章(73)
I. Izquierdo, M. Merlos, J. Garcia-Rafanell, Rupatadine: a new selective histamine H1 receptor and platelet-activating factor (PAF) antagonist. A review of pharmacological profile and clinical management of allergic rhinitis. Drugs of Today. ,vol. 39, pp. 451- 468 ,(2003) , 10.1358/DOT.2003.39.6.799450
Russell L Dedrick, Patricia Walicke, Marvin Garovoy, Anti-adhesion antibodies efalizumab, a humanized anti-CD11a monoclonal antibody. Transplant Immunology. ,vol. 9, pp. 181- 186 ,(2002) , 10.1016/S0966-3274(02)00029-1
Patrick Bernardelli, Bernard Gaudillière, Fabrice Vergne, Chapter 26. To market, to market - 2001 Annual Reports in Medicinal Chemistry. ,vol. 37, pp. 257- 277 ,(2002) , 10.1016/S0065-7743(02)37027-1
Ashay K. Vaishnaw, Christopher N. TenHoor, Pharmacokinetics, biologic activity, and tolerability of alefacept by intravenous and intramuscular administration. Journal of Pharmacokinetics and Pharmacodynamics. ,vol. 29, pp. 415- 426 ,(2002) , 10.1023/A:1022995602257
Takashi KOBAYASHI, Teruhiko INOUE, Shigeyoshi NISHINO, Yoshimi FUJIHARA, Kiyoshi OIZUMI, Tomio KIMURA, Novel 2-amino-1,4-dihydropyridine calcium antagonists. II. Synthesis and antihypertensive effects of 2-amino-1,4-dihydropyridine derivatives having N,N-dialkylaminoalkoxycarbonyl groups at 3- and/or 5-position. Chemical & Pharmaceutical Bulletin. ,vol. 43, pp. 797- 817 ,(1995) , 10.1248/CPB.43.797
Robert J. Bauer, Russell L. Dedrick, Mark L. White, Michael J. Murray, Marvin R. Garovoy, Population Pharmacokinetics and Pharmacodynamics of the Anti-CD11a Antibody hu1124 in Human Subjects with Psoriasis Journal of Pharmacokinetics and Biopharmaceutics. ,vol. 27, pp. 397- 420 ,(1999) , 10.1023/A:1020917122093
Cécile Boyer-Joubert, Edwige Lorthiois, François Moreau, Chapter 33. To market, to market - 2002 Annual Reports in Medicinal Chemistry. ,vol. 38, pp. 347- 374 ,(2003) , 10.1016/S0065-7743(03)38034-0
Bernard Gaudilliere, Patrick Bernardelli, Patrick Berna, Chapter 28. To market, to market — 2000 Annual Reports in Medicinal Chemistry. ,vol. 36, pp. 293- 318 ,(2001) , 10.1016/S0065-7743(01)36068-2
Daniel Campos, Jose Rodrigues Pereira, Rick R. Reinhardt, Carlos Carracedo, Sergio Poli, Conrado Vogel, Jorge Martinez-Cedillo, Aura Erazo, Johanna Wittreich, Lars-Olof Eriksson, Alexandra D. Carides, Barry J. Gertz, Prevention of Cisplatin-Induced Emesis by the Oral Neurokinin-1 Antagonist, MK-869, in Combination With Granisetron and Dexamethasone or With Dexamethasone Alone Journal of Clinical Oncology. ,vol. 19, pp. 1759- 1767 ,(2001) , 10.1200/JCO.2001.19.6.1759
D T Wong, K L Best, F P Bymaster, P G Threlkeld, A new inhibitor of norepinephrine uptake devoid of affinity for receptors in rat brain. Journal of Pharmacology and Experimental Therapeutics. ,vol. 222, pp. 61- 65 ,(1982)